A single-nucleotide polymorphism (SNP) in a human gene can alter the behavior of the corresponding protein, and thereby affect an individual's response to drug therapy. Here, we describe a novel dual-targeting approach for introducing an SNP of choice into virtually any gene, through the use of modified single-stranded oligonucleotides (MSSOs). We use this strategy to create SNPs in a human gene contained in a yeast artificial chromosome (YAC). In the dual-targeting protocol, two different MSSOs are designed to edit two different bases in the same cell. A change in one of these genes is selective while the other is non-selective. We show that the population identified by selective pressure is enriched for cells that bear an edited base at the nonselective site. YACs with human genomic inserts containing particular SNPs or haplotypes can be used for pharmacogenomic applications, in cell lines and in transgenic animals.
INTRODUCTION
In recent years, the nucleotide sequence of a gene and its regulatory domains have become a focus for the field of pharmacogenomics. Now, we recognize that single-nucleotide polymorphisms (SNPs) can drastically affect the activity of the expressed protein and, more importantly, may dictate an altered response to drug therapy. 1 Polymorphisms exist not only in the coding regions of these genes but also in exon-intron boundaries, untranslated regions, and 5 0 -and 3 0 -flanking regions. 2 Appropriate cellular and animal models containing these variations would be crucial in determining the functional significance of any given SNP found in the human population. Simple 'knockout' animal models in which transgenic techniques inactivate a gene are inadequate to assess the impact of SNPs on gene function.
An important consideration in transgenesis is the type of transgene vector that is used. Size restrictions of the typical transgene vector (a plasmid) invariably limit the cloning capacity, resulting in the transgene often containing only the coding region of the gene, but not the natural circuitry that controls its expression. This situation is problematic because genes are naturally positioned and organized into 'expression domains' within chromosomes (see Giraldo and Montoliu 3 and references therein). As directed by evolution, domains include regulatory elements that control the expression and/or suppression of eukaryotic genes. In the absence of these regulatory elements, an exogenous gene used in transgenesis is eventually silenced within a short time. This problem is prolific not only for transgenesis, but also for viral-based gene therapy wherein the therapeutic strategy is to add a 'normal' cDNA to augment dysfunctional gene expression. The yeast Saccharomyces cerevisiae was found to be an ideal host for large pieces of foreign DNA cloned as artificial linear chromosomes. 4 Yeast artificial chromosome (YACs) allow the maintenance and propagation of contiguous segments of foreign DNA up to two megabases in length in an experimentally tractable organism. With the development of YAC vectors, the analysis of complete genes including introns and regulatory regions or multigene loci within the local context of their native environment has been enabled. Although YACs are an ideal vector in terms of the large size of foreign DNA that they can maintain, their large size was also initially a technical difficulty when manipulating the YAC for the generation of transgenic animals. However, now several techniques have been developed for the isolation of intact YACs that have then been used successfully to generate transgenic mice and to transfect mammalian cells by microinjection, electroporation, or lipofection. 5 When introduced into mammalian cells, YACs were found to circumvent positional effects and lead to gene expression in a temporal and regulatable manner.
Nucleotide alteration or gene editing mediated by the use of modified single-stranded oligonucleotides (MSSOs) in eukaryotic cells could in principle occur by different mechanisms. We favor a model (see Figure 1 ) in which the MSSO would first hybridize to one of the two DNA strands and, by design, would create a mismatched base pair at the targeted nucleotide. 6 This structure would be recognized by DNA mismatch repair enzymes, which would promote nucleotide exchange on the target strand with the MSSO serving as a template. Finally, the MSSO would be removed from the site by topological stress, branch migration, and/or other processes. Sequences of the hygromycinresistance gene and its mutation. The mutant hygromycin gene which is integrated in the yeast genome of LSY678IntHyg(rep) contains a point mutation at nucleotide 137 of hygromycin B coding sequence, which makes a replacement mutation of TAT (tyrosine) to TAG (stop codon). Correction of the hygromycin mutation requires the replacement of the mutant G residue with a C residue, restoring the tyrosine amino acid. Note that TAC is different from the wild-type sequence TAT, so that any TAC hygromycin-resistant alleles cannot have arisen from contaminating wild-type TAT cells. Hyg3S/74NT is the MSSO used to correct the hygromycin mutation. It is 74 nucleotides in length and is designed to bind to the nontranscribed strand of the hygromycin gene. The asterisks represent phosphorothioate linkages present in the oligonucleotide. The single mismatch in the MSSO is indicated by the underlined residue. (c) Schematic of the YAC containing the human b-globin locus and the bThal1 and bThal2 sequences that were changed by the corresponding MSSOs. The YAC contains approximately 230 kb of genomic DNA from human chromosome, 11 indicated by the shaded region. The unshaded regions represent the yeast sequences that are on either end of the YAC (not drawn to scale). A portion of the b-globin sequence is shown, beginning with the start codon. bThal1 directs a change from a G to an A, while bThal2 directs a change from a T to a C. The sequences of the MSSOs are shown and are designed to bind to the nontranscribed strand, relative to human transcription of the b-globin locus. The mismatch is centrally located relative to the ends of the MSSO with 35 bases on either side. Both changes result in single-base substitutions that have been documented to result in b-thalassemia in humans. Figure 1 Targeted nucleotide repair. The MSSO searches the chromosomal DNA for sequence complementarity and, once found, aligns in homologous register with the target site. Upon hybridization, a single mismatched base pair is created between the MSSO and the gene sequence. This mismatch is then repaired by enzymes from the DNA repair pathways, resulting in the conversion of a C-G base pair to an A-T. The MSSO is represented by the green helical molecule, and each putative repair stage is designated.
Our earlier work concentrated on optimizing the efficiency of gene editing of point, deletion, and insertion mutations, with particular attention paid to DNA metabolism, including the activity of DNA repair proteins. Targeting is enhanced when hydroxyurea (HU), which slows the rate of DNA replication, and trichostatin A (TSA), which blocks histone deacetylation, are included in the reaction. 7 The mechanism of this enhancement likely includes the alteration of the chromosomal environment, allowing greater target accessibility. In addition, the role of Rad51p is now known to be critical, presumably to promote DNA pairing in a reaction that assimilates the MSSO into the target site. 8 A major difference in attempting to target human sequences within a YAC compared to the yeast experiments used previously is the fact that any single-base changes in the YAC insert would likely not have any selectable phenotype in yeast. Thus, the absolute efficiency of the gene editing process was crucial since pure clones with edited sequences would be identified by screening, not selection. For that reason, we designed a novel dualtargeting strategy to target genes in YACs. Based on our overall understanding of the mechanism of gene editing, we hypothesized that a subpopulation of yeast cells are amenable to the entire process. This subpopulation may not only be capable of creating a single-base change directed by a single oligonucleotide, but if presented with a second oligonucleotide (or more), a second change (or more) would be enabled in the same cell. Indeed, introducing different MSSOs at the same time increases the overall editing frequency, 9, 10 perhaps by acting synergistically to increase DNA repair activity throughout the cell. In the dualtargeting protocol we describe here, two different MSSOs are designed to edit two different bases in the same cell. One of these genes is selective while the other is nonselective. Thus, the population identified by selective pressure will be enriched for cells that bear an edited base at the nonselective site.
RESULTS AND DISCUSSION
The dual-targeting strategy is illustrated in Figure 2a . The LSY678IntHyg(rep)b 8,11,12 strain (Table 1) contains a 240 kb human b S -globin YAC and a cassette containing a chromosomal hygromycin-resistance gene inactivated by a singlebase mutation and a functional aureobasidin-resistance gene integrated into the yeast genome. Figure 2b shows the MSSO used to direct editing of the chromosomal hygromycin mutant gene. Hyg3S/74NT is a 74-mer that is specific for binding to the nontranscribed strand and contains three terminal phosphorothioate linkages. 8, 11, 12 Also shown is the target sequence of the mutant, which contains a TAG stop codon. Figure 2c illustrates the structure of the b-globin YAC and nucleotides targeted for editing are specified. The two nonselectable changes will be directed by different MSSOs, bThal1 and bThal2, in separate experiments.
For editing, YAC-containing LSY678IntHyg(rep)b cells (Table 1) were grown in the presence of HU, electroporated with both MSSOs, and allowed to recover in the presence of TSA (Figure 2a) . As the human b-globin gene is likely to be transcriptionally inactive in yeast, HU and TSA were anticipated to be especially important in increasing target accessibility. The results of dual-targeting experiments are presented in Figure 3a . Hygromycin-resistant colonies are observed when the specific targeting vehicle, Hyg3S/74NT, is used. The ratio of hygromycin-resistant colonies to aureobasidin-resistant colonies is referred to as the correction efficiency (CE). The presence of HU and TSA led to an increase in the CE of the hygromycin mutation, here about four-to six-fold. In this experiment, hygromycin-resistant colonies were found at roughly one per 3000 aureobasidinresistant colonies. Hygromycin-resistant colonies were then analyzed for second-site editing in the YAC b-globin gene. The bThal1 MSSO is designed to direct the replacement of a G in TGG codon 16 of exon 1 with an A, giving the stop codon TGA (Figure 2c) . Figure 3b shows an ABI SNaPshot (middle panels) and direct DNA sequence (bottom panel) of a region of the b-globin gene in a corrected colony from this experiment; in both, the G-A change is evident. Of those colonies that had corrected the hygromycin mutation, one Figure 3 (a) Efficiency of gene editing of hygromycin mutation using the dual-targeting protocol. The CE is plotted for gene editing of the hygromycin mutation when a single MSSO (Hyg3S/74NT) was used compared with two MSSOs (Hyg3S/74NT and bThal1). In each experiment, cells were grown either in the absence (white bars) or presence (filled bars) of HU and TSA. CE is determined by the number of corrected hygromycin-resistant cells over the total number of targetable cells (determined by aureobasidin resistance) (see Figure 2a) . When the MSSO specific for correction of the hygromycin mutation, Hyg3S/74NT, is used in the absence of HU or TSA, the CE of the mutant hygromycin gene was B3 Â 10
À5
. The treatment of cells with HU and TSA results in a stimulation of gene editing, increasing the CE to B12 Â 10 À5 . When two MSSOs were used, one specific to correction of the hygromycin mutation, and one directed to the human bglobin locus, the CE of the mutant hygromycin gene in the absence of HU and TSA was B5 Â 10 À5 and in the presence of HU and TSA increased to B31 Â 10 À5 or 0.03%. (b) Gene editing of the human b-globin gene directed by the bThal1 MSSO. A portion of the human bglobin gene is shown, indicating the single-base change created by the bThal1 MSSO (G-A). Analysis reports of SNaPshot reactions using the ABI GeneScan software are shown for an unconverted clone and a converted clone. The orange peaks are size standards used in the reaction. The SNaPshot primer (see experimental protocol) is designed to anneal and extend one base at the position of the SNP of interest using a pool of fluorescently tagged dideoxynucleotides. The black peak indicates the presence of a G at that position (unconverted), while a green peak indicates the presence of an A at that position (converted). Approximately 1/300 of the hygromycin-corrected cells also had made the bThal1 change. All clones that showed conversion by SNaPshot analysis were confirmed to have made the single-base change by standard sequencing and the sequencing trace for that portion of the b-globin gene is shown, with the converted residue being indicated by the arrow. The above strain containing an episomal expression plasmid overexpressing RAD51 in 325 also contained the second change in the YAC bglobin sequence. Thus, the second-site change in the bglobin gene occurs at a 10-fold higher frequency among hygromycin-corrected colonies compared with the frequency of hygromycin correction in the total population of cells.
In previous work, we found that overexpression of ScRAD51 consistently increased the frequency of chromosomal gene editing. 8 Accordingly, we introduced an expression plasmid containing the ScRAD51gene into LSY678IntHyg(rep)b cells (Table 1 ). Figure 4 shows results of dual targeting in this strain and, as expected, expression of Pharmacogenomics using eukaryotic model systems
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ScRAD51 increased the hygromycin CE of MSSO Hyg3S/ 74NT (compare with Figure 3 ). Here too, addition of a second MSSO, bThal2, increased the CE further, to roughly one hygromycin-resistant colony per 800 aureobasidinresistant colonies.
The bThal2 MSSO is designed to direct the replacement of a T in the initiator ATG codon of exon 1 with a C, giving the noninitiator codon ACG (Figure 2c) . Figure 4b shows an ABI SNaPshot (middle panels) and direct DNA sequence (bottom panel) of the b-globin gene from a corrected Hyg r colony; Pharmacogenomics using eukaryotic model systems
the T-C change is evident in both analytical panels. Importantly, of these colonies that had corrected the hygromycin mutation, one in 70 also contained the second single-base change in the YAC b-globin sequence. Thus, the dual-targeting approach was again successful; the edited bglobin gene occurs at a 10-fold higher frequency when compared to the frequency of the total population that bears the corrected hygromycin. However, in the presence of high levels of ScRad51, gene editing occurs at a higher level, indicating that the presence of HU, TSA, and RAD51 overexpression exhibit synergistic effects on the overall process. The recent development of new transgenic constructs complementary to the YAC system, such as bacterial artificial chromosomes (BACs) or phage artificial chromosomes (PACs), has enabled the creation of tools for functional genomics (see, for review, Copeland et al 13 ). Indeed, several reports [14] [15] [16] [17] [18] have described modifications of human genes in bacteria; Swaminathan et al 18 have used a single-stranded oligonucleotide to introduce mutations in a BAC in Escherichia coli. While these reports have solidified and validated the overall strategy, there are limitations to this approach when BACs or PACs are used. In particular, BAC modifications must be conducted in a specially engineered strain, while our method can be used in essentially any genetic background, targeting either a plasmid or a chromosome. 8, 11, 12 More importantly, BACs have a restricted length of foreign DNA (p300 kb) capable of being stably maintained, while YACs can hold up to 2 Mb (see, for review, Huxley 19 ). Therefore, YACs enable targeting of introns and regulatory as well as coding regions, and could reveal interactions between genes linked too loosely to be present on a single BAC or PAC. Finally, our understanding of the role of proteins integral to the gene editing process in yeast (ie RAD51) that have mammalian homologues is likely to be useful for translating the process to mammalian cells rather than relying on bacterial or phage proteins.
In summary, we present a novel approach to creating SNPs in human genes that employs the use of MSSOs to create single-base changes in YACs. Gene editing uses a dualtargeting approach, in combination with HU, TSA, and expression of ScRAD51, and allows the ready identification of a nonselected single-base change in a YAC. In our best experiments, a YAC gene is found to be edited in roughly 100 hygromycin-resistant colonies, which is quite practical. We expect this new technique to be useful for the construction of collections of cells or animals that differ only in a single SNP; these models can serve as tools for understanding the functional role of SNPs.
MATERIALS AND METHODS

Strains
The genotypes of the yeast strains used in these studies are listed in Table 1 . Details of the LSY678IntHyg(rep) strain have been published. 12 
YAC manipulations
The b-globin YAC was isolated from a preparative pulsedfield gel as described previously. 20 Briefly, concentrated chromosomal DNA from the b S -YAC strain (AB1380 background) 21 was prepared and resolved on a 1% low-melt agarose pulsed-field gel at 200 V, 141C, 20-50 s, 33 h. The YAC was isolated, equilibrated with a modified agarase buffer (10 mM BisTris-HCl pH 6.5, 1 mM EDTA, 100 mM NaCl), treated with b-agarase I (New England Biolabs), and concentrated to a final volume of B200 ml. A volume of 30 ml of the purified YAC were introduced into competent LSY678IntHyg(rep) cells by spheroplast transformation and selection on agar/sorbitol plates lacking tryptophan. Transformants were restreaked and confirmed by pulsed-field gel electrophoresis, PCR, and sequence analysis for a fragment of the human b-globin gene.
The pYNARad51 episomal expression plasmid was constructed by replacing the TRP1 gene of pYNRad51 with the ADE2 gene. pYNARad51 was introduced into LSY678IntHy- Figure 4 (a) Efficiency of gene editing of hygromycin mutation using the dual-targeting protocol in combination with overexpression of yeast Rad51. The CE is plotted for gene editing of the hygromycin mutation when a single MSSO (Hyg3S/74NT) was used compared with two MSSOs (Hyg3S/74NT and bThal2) or a nonspecific oligonucleotide (KanUD3/71). In each experiment, cells containing pYNARad51 (white bars) or no overexpression plasmid (filled bars) were grown with HU and TSA treatment. pYNARad51 is an episomal expression plasmid with RAD51 under the control of a constitutive promoter and was introduced into cells prior to the targeting experiment. CE is determined by the number of corrected hygromycin-resistant cells over the total number of targetable cells (determined by aureobasidin resistance). When the MSSO specific for correction of the hygromycin mutation, Hyg3S/74NT, is used in the absence of overexpression of Rad51, the CE of the mutant hygromycin gene was B13 Â 10
À5
, similar to the results in Figure 3a . Overexpression of RAD51 results in a dramatic stimulation of gene editing, increasing the CE to B97 Â 10 À5 . When two MSSOs were used, one specific to correction of the hygromycin mutation, and one directed to the human b-globin locus, the CE of the mutant hygromycin gene in the absence of excess Rad51 was B45 Â 10
, again similar to Figure 3a . In the presence of pYNARad51, the CE increased to B124 Â 10 À5 or 0.1%. (b) Gene editing of the human b-globin gene directed by the bThal2 MSSO. A portion of the human b-globin gene is shown, indicating the singlebase change created by the bThal2 MSSO (T-C). Analysis reports of SNaPshot reactions using the ABI GeneScan software are shown for an unconverted clone and a converted clone. The orange peaks are size standards used in the reaction. The SNaPshot primer (see experimental protocol) is designed to anneal and extend one base at the position of the SNP of interest using a pool of fluorescently tagged dideoxynucleotides. The red peak indicates the presence of a T at that position (unconverted), while a blue peak indicates the presence of a C at that position (converted). Approximately 1% of the hygromycin-corrected cells also had made the bThal2 change. All clones that showed conversion by SNaPshot analysis were confirmed to have made the single-base change by standard sequencing and the sequencing trace for that portion of the b-globin gene is shown, with the converted residue being indicated by the arrow. g(rep)b by electroporation and selection on agar plates lacking adenine.
Oligonucleotides
Hyg3S/74NT, bThal1, and bThal2 are the targeting oligonucleotides (MSSOs) used in this paper and were ordered from IDT with HPLC purification. Hyg3S/74NT is a 74mer and both bThal1 and bThal2 are 71mers; all three oligonucleotides have three phosphorothioate linkages at the 5 0 -and 3 0 -end (Figure 2 ).
Dual targeting
The dual-targeting protocol is outlined in Figure 2a . LSY678IntHyg(rep)b cells were grown overnight in 10 ml YPD media at 301C. The culture was diluted to OD 600 B0.15-0.20 in 40 ml YPD media and grown for one doubling time to OD 600 B0.3-0.4. HU (100 mM) was added to the culture and the cells were grown for one doubling time to OD 600 B0.6-0.8. Cells were harvested and resuspended in 1 ml YPD containing 25 ml 1 M DTT and grown for an additional 20 min at 301C. The cells were washed twice with 25 ml cold dH 2 O and once with 25 ml cold 1 M sorbitol. The cells were resuspended gently in 1 ml cold 1 M sorbitol, spun for 5 min at 5000 rpm in a microcentrifuge, and resuspended in 120 ml 1 M sorbitol. Cells (40 ml) were electroporated with 30 mg of each oligo in a 2 mm gap cuvette using a Bio-Rad Gene Pulser apparatus (Richmond, CA, USA) with 1.5 kV, 25 mF, 200 O, 1 pulse, 5 s/pulsed length. The cells were immediately resuspended in 3 ml YPD/sorbitol with 0.8 mg/ ml aureobasidin A and 50 mg/ml TSA and recovered overnight at 301C. The cells were spun down and resuspended in 1 ml fresh YPD. Dilutions were plated on YPD agar plates containing either hygromycin (300 mg/ml) or aureobasidin A (0.5 mg/ml). CEs were determined based on the number of hygromycin-resistant colonies per aureobasidin-resistant colonies.
Individual colonies were picked from the hygromycin agar plates into 96-well plates (Corning) containing 150 ml YPD and grown overnight at 301C with shaking. A 345 bp PCR product specific for the human b-globin locus was amplified from each of the 96 wells using the primers PCO2 and PCO5 in order to screen for the bThal1 or bThal2 conversion. The sequence of PCO2 is as follows: 5 0 -TCCTAAGCCAGTGCCAGAAG-3 0 . The sequence of PCO5 is as follows: 5 0 -CTATTGGTCTCCTTAAACCTG-3 0 . The PCR reactions were performed by adding 8 pmol of each primer and 2.5 ml yeast cell culture into prealiquoted PCR reaction mixes (Marsh/Abgene). The PCR reactions used an annealing temperature of 45.81C and an extension time of 1 min for 35 cycles. The PCR reactions were purified using a QiaQuick PCR 96-well purification kit (Qiagen) and eluted in a volume of 80 ml. A volume of 1 ml of the purified PCR product was used as a template for the ABI SNaPshot reaction. The sequence of the SNaPshot primer used to screen for the bThal1 conversion is: 5 0 -CCCCCC-CCCCCCCCCCCAAGTCTGCCGTTACTGCCCTGTG-3 0 . The sequence of the SNaPshot primer used to screen for the bThal2 conversion is: 5 0 -TTTTTTTTTTTTTTTTTTTTTTTTT-TTTTTTTTTCCACAGGAGTCAGGTGCACC-3 0 . The SNaPshot reactions were performed using an ABI Prism SNaPshot Multiplex Kit, as specified by the manufacturer, and analyzed on an ABI 3100 Genetic Analyzer.
Sequence analysis
Any potential converted clones from the SNaPshot reactions were confirmed by sequence analysis. Both strands of the PCR products were sequenced using primers PCO2 and PCO5 by Sanger dideoxy sequencing using an ABI Prism kit, as specified by the manufacturer, on an automated ABI 3100 Genetic Analyzer.
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